CapsoVision, a leading innovator in capsule endoscopy, has officially entered the public market, closing its initial public offering (IPO) and beginning trading on the Nasdaq Capital Market under the ticker symbol “CV.”
The IPO comprised 5.5 million shares of common stock, priced at $5 per share, raising approximately $27.5 million in gross proceeds before underwriting discounts, commissions, and other offering-related expenses. Additionally, the company has granted underwriters a 30-day option to purchase up to 825,000 additional shares at the same offering price.
CapsoVision now joins a small but growing group of medtech companies that have recently gone public, including wearable defibrillator company Kestra Medical ($202 million IPO in March) and Beta Bionics ($204 million IPO in January). Other notable IPOs in the medtech space over the past year include Anteris Technologies and neurotechnology firm CeriBell. Meanwhile, Medline and Carlsmed are also preparing for public listings.
The funds raised from the IPO are expected to support CapsoVision’s continued innovation and commercialization of its flagship product, CapsoCam Plus — an advanced, AI-powered capsule endoscopy system. Unlike traditional endoscopy, CapsoCam Plus offers a non-invasive and patient-friendly diagnostic experience through a swallowable capsule equipped with four cameras that capture a 360-degree panoramic view of the small intestine.
This comprehensive lateral view allows physicians to directly visualize the mucosal surface, improving detection of abnormalities and lesions that may be missed with conventional “forward-looking” endoscopes.
The system is further supported by CapsoCloud, the company’s proprietary cloud-based platform that enables clinicians to seamlessly access and review diagnostic results online. The integration of cloud technology not only enhances diagnostic accuracy but also improves workflow efficiency and reduces overall procedure time.
With its Nasdaq debut, CapsoVision is poised to scale its impact in the gastrointestinal diagnostics market and drive wider adoption of its cutting-edge technology in clinical practice.